Clinical trials
Breast clinical trials
Below are recruiting breast clinical trials, each written for real people, not researchers. We’re tracking 2,627 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06185569Recruiting
French study on outcomes in HR+/HER2- early breast cancer patients with Oncotype DX
This study looks at how well treatments work for people with early-stage, hormone receptor-positive, HER2-negative breast cancer when the Oncotype DX test helps guide therapy. It aims to understand real-world outcomes in French patients.
BesançonAges 18 years+ - NCT06162559RecruitingPhase 1
Targeted therapy before surgery for HER2+ breast cancer
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
AmsterdamAges 18 years+ - NCT07869641Recruiting
Breast enlargement using your own fat
This study tests a procedure that uses your own fat to make your breasts larger. It aims to see if this method is safe and effective for women who want breast enlargement.
EdegemAges 18–55 - NCT07854262Recruiting
Shock wave therapy for arm swelling after breast cancer
This study tests whether a treatment called extracorporeal shock wave therapy (ESWT), which uses sound waves, can reduce arm swelling (lymphedema) that some people get after breast cancer treatment. It may help if you have had arm swelling for less than 4 years and have finished your cancer treatment.
AnkaraAges 18 years+ - NCT06234137Recruiting
Chemo plus targeted therapy for advanced HER2+ breast cancer
This trial tests a combination of chemotherapy (docetaxel and carboplatin) plus two targeted drugs (Inetetamab and Pyrotinib) for people with locally advanced HER2-positive breast cancer that has not spread to other parts of the body. The goal is to see if this powerful combo can shrink the tumor before surgery or other treatments.
Wenzhou, ZhejiangAges 18–75 - NCT06169072RecruitingPhase 2
Finding lymph nodes with a tiny dose of magnetic tracer in breast cancer
This trial is testing whether a very small amount of a magnetic tracer called Magtrace can help find lymph nodes that need to be checked for cancer spread during breast cancer surgery.
GothenburgAges 18 years+ - NCT07870148Recruiting
Breast cancer and thyroid antibodies study
This study looks at whether the body's immune response to the thyroid is linked to breast cancer. It may help doctors understand how breast cancer behaves and how to treat it better.
MilanAges 18–80 - NCT05159193RecruitingPhase 3
Pre-surgery chemotherapy and antibodies for HER2 breast cancer
This phase 3 trial compares two pre-surgery treatment plans for people with HER2-positive invasive breast cancer that has spread to nearby lymph nodes. It aims to see which plan works better to shrink the tumor before surgery and improve outcomes.
Guandong, GuangdongAges 18–70 - NCT02839863Recruiting
Breast cancer care follow-up at UMC Utrecht with surveys
This study follows people with breast cancer who receive radiation at UMC Utrecht. It uses routinely collected medical data and questionnaires to better understand outcomes over the long term.
AlmeloAges 18 years+ - NCT05759546RecruitingPhase 2
Test a PARP and CDK4/6 medicine plus hormone therapy
This Phase 2 study tests whether combining a PARP inhibitor with a CDK4/6 inhibitor and hormone (endocrine) therapy can help people with advanced HR-positive, HER2-negative breast cancer. It’s for certain patients who have not yet had chemotherapy or targeted therapy for metastatic disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05891093RecruitingPhase 3
Fluzoparib plus hormone therapy after surgery for breast cancer
This Phase 3 trial tests whether fluzoparib added to standard hormone (endocrine) therapy after early breast cancer surgery can improve outcomes and safety. It may help patients whose tumors are ER-positive, HER2-negative, and a specific SNF3 subtype.
Beijing, Beijing MunicipalityAges 18–70 - NCT06254690RecruitingPhase 2
Pyrotinib dosing study for HER2-positive advanced breast cancer
This trial tests different doses of pyrotinib, a targeted therapy, for women with HER2-positive advanced breast cancer that has not yet been treated for recurrence. It aims to find the best dosing regimen to control the cancer.
Nanjing, JiangsuAges 18–70 - NCT06259162Recruiting
LAG3 study in triple-negative breast cancer
This trial is studying a protein called LAG3 in triple-negative breast cancer. It is for people who will receive chemotherapy before surgery to see if LAG3 levels affect how well the treatment works.
SeoulAges Any age - NCT05999149RecruitingPhase 3
Famitinib plus chemo and immunotherapy before breast cancer surgery
This trial tests whether adding a targeted therapy pill (famitinib) to standard chemo plus an immunotherapy (camrelizumab) can shrink triple negative breast cancer before surgery. It may help people with earlier-stage disease who have not had certain prior treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06278870RecruitingPhase 3
New drug combo vs standard for HER2+ advanced breast cancer
This trial compares two drug combinations for HER2-positive breast cancer that has spread. It tests a newer drug (Disitamab Vedotin + Pyrotinib) against a standard treatment (THP) as a first treatment option.
Guangzhou, GuangdongAges 18–75 - NCT06281145Recruiting
Stress reduction for breast or colon cancer patients
This study tests a stress-reducing program for people with breast or colon cancer. It uses a technique called heart rate variability biofeedback to help you manage stress during treatment.
BratislavaAges 18 years+ - NCT07859046Enrolling by invitation
Imaging test to guide treatment for ER-positive breast cancer
This trial uses a special imaging scan called 18F-FES PET/CT to help doctors plan treatment and check how well it works for breast cancer that is ER-positive (meaning the cancer cells grow in response to estrogen). It may help improve treatment choices and monitoring.
Changsha, HunanAges 18–80 - NCT06282796Recruiting
Early heart risk monitoring for breast cancer chemo
This study tests a method to predict and warn about heart damage from a common type of breast cancer chemotherapy. If you have HER2-positive breast cancer and will receive anthracycline drugs, this trial may help monitor your heart health.
Fuzhou, FujianAges 18–80 - NCT06286267Recruiting
AI tool for diagnosing breast phyllodes tumors
This trial uses an artificial intelligence system to help doctors more accurately diagnose and predict the outcome of breast phyllodes tumors, which are rare breast growths. It aims to improve how these tumors are identified and managed.
Guangzhou, GuangdongAges Any age - NCT06315868Recruiting
Breast cancer organoid study for tumor analysis
This study is testing a new way to understand your breast cancer by growing tiny tumor samples (called organoids) in the lab. It will help researchers learn more about your cancer type and could lead to better treatments.
RomaAges 18–70 - NCT06227117RecruitingPhase 2
Study of DV and Toripalimab before surgery for HER2-low breast cancer
This trial tests a combination of two drugs (DV and Toripalimab) with chemotherapy before surgery for a specific type of breast cancer (HER2-low, HR-negative) that has not spread too far. The goal is to see if this approach can shrink the tumor and improve outcomes.
Changsha, HunanAges 18 years+ - NCT05861271RecruitingPhase 2
Adjuvant pyrotinib plus capecitabine for tiny HER2 breast cancer
This trial studies whether adding pyrotinib and capecitabine after surgery can lower the risk of cancer coming back in people with very small, lymph-node–negative, HER2-positive breast cancer. It’s for patients who fit specific tumor size and HER2 test results and who can safely take chemotherapy-like medicines and stay on contraception during treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05433753Recruiting
Study for leftover cancer DNA in HER2-positive early breast cancer
This study looks for tiny traces of cancer after treatment by testing blood for “ctDNA,” which is leftover cancer DNA. It includes people with HER2-positive early breast cancer who are getting chemotherapy before surgery to see if this blood test can detect signs of remaining disease.
Chuo-ku, TokyoAges 20 years+ - NCT06330012Recruiting
Understanding resistance to T-Dxd in HER2+ breast cancer
This study looks at why some HER2-positive breast cancer patients stop responding to the drug T-Dxd (trastuzumab deruxtecan). It aims to find out how resistance develops, which may help improve future treatments.
SeoulAges Any age
Hear when a new Breast trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast?
- Yes. Clin2 currently lists 2,627 recruiting breast studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.